Paclitaxel improved anti-L1CAM lutetium-177 radioimmunotherapy in an ovarian cancer xenograft model
出版年份 2014 全文链接
标题
Paclitaxel improved anti-L1CAM lutetium-177 radioimmunotherapy in an ovarian cancer xenograft model
作者
关键词
177Lu-radioimmunotherapy, Paclitaxel, Combination therapy, Ovarian carcinoma, L1CAM, mAb chCE7
出版物
EJNMMI Research
Volume 4, Issue 1, Pages -
出版商
Springer Nature
发表日期
2014-10-02
DOI
10.1186/s13550-014-0054-2
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model
- (2014) Jürgen Grünberg et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Defining Risks of Taxane Neuropathy: Insights from Randomized Clinical Trials
- (2013) D. Kudlowitz et al. CLINICAL CANCER RESEARCH
- Monoclonal antibodies therapies for ovarian cancer
- (2013) Umberto Leone Roberti Maggiore et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Microtubule stabilising agents and ionising radiation: Multiple exploitable mechanisms for combined treatment
- (2012) Carla Rohrer Bley et al. EUROPEAN JOURNAL OF CANCER
- Enhanced efficacy of combined 213Bi-DTPA-F3 and paclitaxel therapy of peritoneal carcinomatosis is mediated by enhanced induction of apoptosis and G2/M phase arrest
- (2012) Mario Vallon et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- L1CAM
- (2012) Helena Kiefel et al. Cell Adhesion & Migration
- Recent progress in the diagnosis and treatment of ovarian cancer
- (2011) Danijela Jelovac et al. CA-A CANCER JOURNAL FOR CLINICIANS
- L1-CAM-targeted antibody therapy and 177Lu-radioimmunotherapy of disseminated ovarian cancer
- (2011) Eliane Fischer et al. INTERNATIONAL JOURNAL OF CANCER
- Clinical radioimmunotherapy—the role of radiobiology
- (2011) Jean-Pierre Pouget et al. Nature Reviews Clinical Oncology
- Combined-modality radioimmunotherapy: synergistic effect of paclitaxel and additive effect of bevacizumab
- (2011) Beom-Su Jang et al. NUCLEAR MEDICINE AND BIOLOGY
- The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial
- (2010) Markus M. Heiss et al. INTERNATIONAL JOURNAL OF CANCER
- The detection, treatment, and biology of epithelial ovarian cancer
- (2010) Jennifer A.A. Gubbels et al. Journal of Ovarian Research
- Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer
- (2009) Peter J. Frederick et al. GYNECOLOGIC ONCOLOGY
- Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash
- (2009) Russell J. Schilder et al. GYNECOLOGIC ONCOLOGY
- The soluble form of the cancer-associated L1 cell adhesion molecule is a pro-angiogenic factor
- (2009) Alexandra Friedli et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Antibodies directed against L1-CAM synergize with Genistein in inhibiting growth and survival pathways in SKOV3ip human ovarian cancer cells
- (2008) Ilse Novak-Hofer et al. CANCER LETTERS
- Multimodality Therapy: Potentiation of High Linear Energy Transfer Radiation with Paclitaxel for the Treatment of Disseminated Peritoneal Disease
- (2008) D. E. Milenic et al. CLINICAL CANCER RESEARCH
- L1-CAM in cancerous tissues
- (2008) Nancy Gavert et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer
- (2008) Jonathan Berek et al. JOURNAL OF CLINICAL ONCOLOGY
- Enhanced L1CAM expression on pancreatic tumor endothelium mediates selective tumor cell transmigration
- (2008) Yasmin Issa et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Therapeutic efficacy of177Lu-CHX-A″-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy
- (2008) Marcus P. Kelly et al. PROSTATE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started